Aveo Pharmaceuticals, Inc.

Pd-1 Acquisition Group, LLC

Osi Pharmaceuticals, Inc.

Maria Isabel Chiu

Lorena Lerner

Ting Chen

Ailin Bai

Jeno Gyuris

William M Winston, Jr

Solly Weiler

Zhigang Weng

Laura L Poling

Sandra Abbott

Qing Liu

Nianjun Tao

Bin Feng

Vikki A Spaulding

Daniel Doty

Hareesh Chamarthi

Aleksander Jonca

Thomas McQuade

Anhco Nguyen

Sheila Ranganath

Hans Albert Felix Scheuplein

Lei Wang

Jennifer Watkins-Yoon

Sri Sahitya Vadde

Najmia Amirina

Murray Robinson

Jie Lin

Ronan O'Hagan

Julie Kan

Yinghui Zhou

Stuart Thomson

Matthew O'Connor

Joerg Heyer

Richard Nicoletti

Karuppiah Kannan

Ti Cai

Gretchen M Argast

William M Winston

Laura Poling

Thomas Mcquade

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Anti-GDF-15 antibodies

Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.

Anti-PD-1 antibodies

Anti-GDF15 antibodies

The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.

Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment

Methods of treatment using anti-GDF15 antibodies

A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

Directed complementation

Growing community of inventors

Newton Centre, MA, United States of America

Maria Isabel Chiu